Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: Pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials: COMPLICATIONS

Journal of Interventional Cardiology

Volumn 22, Issue 5, 2009, Pages 453-459

  Doll, Jacob A ^a   Nikolsky, Eugenia ^a,d   Stone, Gregg W ^a   Mehran, Roxana ^a   Lincoff, A Michael ^b   Caixeta, Adriano ^a   McLaurin, Brent ^a,c   Cristea, Ecaterina ^a   Fahy, Martin ^a   Kesanakurthy, Vijaya ^a   Lansky, Alexandra J ^a  

^a NewYork Presbyterian Hospital   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ANMED HEALTH   (United States)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; PACLITAXEL; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY PERFORATION; CREATININE CLEARANCE; DEATH; DRUG ELUTING STENT; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANTICOAGULANTS; CHEMOTHERAPY, ADJUVANT; CORONARY VESSELS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; WOUNDS, PENETRATING;

EID: 70349754509     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00494.x     Document Type: Article

References (16)

1. Dippel EJ, Kereiakes DJ, Tramuta DA, et al. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management. Catheter Cardiovasc Interv 2001 52 : 279 286.
2. Javaid A, Buch AN, Satler LF, et al. Management and outcomes of coronary artery perforation during percutaneous coronary intervention. Am J Cardiol 2006 98 : 911 914.
3. Fasseas P, Orford JL, Panetta CJ, et al. Incidence, correlates, management, and clinical outcome of coronary perforation: Analysis of 16,298 procedures. Am Heart J 2004 147 : 140 145.
4. Fukutomi T, Suzuki T, Popma JJ, et al. Early and late clinical outcomes following coronary perforation in patients undergoing percutaneous coronary intervention. Circ J 2002 66 : 349 356.
5. Gruberg L, Pinnow E, Flood R, et al. Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention. Am J Cardiol 2000 86 : 680 682, A688.
6. Ramana RK, Arab D, Joyal D, et al. Coronary artery perforation during percutaneous coronary intervention: Incidence and outcomes in the new interventional era. J Invasive Cardiol 2005 17 : 603 605.
7. Stankovic G, Orlic D, Corvaja N, et al. Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. Am J Cardiol 2004 93 : 213 216.
8. Witzke CF, Martin-Herrero F, Clarke SC, et al. The changing pattern of coronary perforation during percutaneous coronary intervention in the new device era. J Invasive Cardiol 2004 16 : 257 301.
9. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994 343 : 881 886.
10. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997 349 : 1429 1435.
11. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 336 : 1689 1696.
12. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998 352 : 87 92.
13. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 289 : 853 863.
14. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial. JAMA 2007 298 : 2497 2506.
15. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008 358 : 2218 2230.
16. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation 1994 90 : 2725 2730.